Summit Trail Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.03M | Sell |
209,089
-9,069
| -4% | -$237K | 0.06% | 181 |
|
|
2026
Q1 | $6.13M | Sell |
218,158
-7,532
| -3% | -$201K | 0.09% | 126 |
|
|
2025
Q4 | $5.62M | Buy |
225,690
+2,670
| +1% | +$67.3K | 0.1% | 113 |
|
|
2025
Q3 | $5.68M | Buy |
223,020
+52,489
| +31% | +$1.3M | 0.08% | 126 |
|
|
2025
Q2 | $4.13M | Buy |
+170,531
| New | +$3.98M | 0.07% | 144 |
|
|
2024
Q4 | – | Sell |
-113,684
| Closed | -$3.29M | – | 660 |
|
|
2024
Q3 | $3.29M | Sell |
113,684
-22,057
| -16% | -$643K | 0.08% | 112 |
|
|
2024
Q2 | $3.8M | Buy |
135,741
+77,293
| +132% | +$2.13M | 0.1% | 85 |
|
|
2024
Q1 | $1.62M | Buy |
58,448
+13,510
| +30% | +$375K | 0.04% | 155 |
|
|
2023
Q4 | $1.29M | Sell |
44,938
-17,217
| -28% | -$520K | 0.04% | 138 |
|
|
2023
Q3 | $2.06M | Buy |
62,155
+239
| +0.4% | +$8.45K | 0.08% | 95 |
|
|
2023
Q2 | $2.27M | Buy |
61,916
+12,971
| +27% | +$505K | 0.09% | 95 |
|
|
2023
Q1 | $2M | Buy |
48,945
+5,547
| +13% | +$240K | 0.08% | 85 |
|
|
2022
Q4 | $2.22M | Buy |
43,398
+4,634
| +12% | +$222K | 0.1% | 71 |
|
|
2022
Q3 | $1.7M | Sell |
38,764
-4,033
| -9% | -$196K | 0.09% | 78 |
|
|
2022
Q2 | $2.24M | Buy |
42,797
+10,734
| +33% | +$547K | 0.14% | 71 |
|
|
2022
Q1 | $1.66M | Buy |
32,063
+4,724
| +17% | +$245K | 0.13% | 79 |
|
|
2021
Q4 | $1.61M | Buy |
27,339
+587
| +2% | +$29.1K | 0.1% | 102 |
|
|
2021
Q3 | $1.15M | Buy |
26,752
+2,400
| +10% | +$106K | 0.09% | 106 |
|
|
2021
Q2 | $954K | Buy |
24,352
+699
| +3% | +$27.2K | 0.08% | 108 |
|
|
2021
Q1 | $857K | Sell |
23,653
-1,680
| -7% | -$59.6K | 0.09% | 94 |
|
|
2020
Q4 | $933K | Buy |
+25,333
| New | +$929K | 0.12% | 77 |
|
|
2020
Q3 | – | Sell |
-24,412
| Closed | -$757K | – | 226 |
|
|
2020
Q2 | $757K | Buy |
24,412
+987
| +4% | +$33.5K | 0.14% | 66 |
|
|
2020
Q1 | $725K | Buy |
+23,425
| New | +$798K | 0.2% | 54 |
|
|
2019
Q4 | – | Sell |
-19,911
| Closed | -$679K | – | 102 |
|
|
2019
Q3 | $679K | Buy |
19,911
+2,650
| +15% | +$96.4K | 0.24% | 39 |
|
|
2019
Q2 | $709K | Buy |
17,261
+650
| +4% | +$25.8K | 0.31% | 35 |
|
|
2019
Q1 | $669K | Buy |
+16,611
| New | +$665K | 0.29% | 37 |
|
|
2018
Q2 | – | Sell |
-63,421
| Closed | -$1.48M | – | 623 |
|
|
2018
Q1 | $1.48M | Buy |
63,421
+14,105
| +29% | +$485K | 0.25% | 89 |
|
|
2017
Q4 | $1.72M | Buy |
+49,316
| New | +$1.68M | 0.22% | 88 |
|
Other funds holding PFE
Summit Trail Advisors's PFE Position: Q2 2026 in Review
Summit Trail Advisors reduced its Pfizer (PFE) stake by 4.2% in Q2 2026, selling an estimated $237K and leaving 209,089 shares worth $5.03M. The position accounts for 0.06% of the portfolio, ranked #181.
Summit Trail Advisors first reported a position in PFE in Q4 2017 and has held it in 28 quarters since. The position peaked at $6.13M in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Summit Trail Advisors held 209,089 shares of Pfizer worth $5.03M as of Q2 2026.
- Summit Trail Advisors sold 9,069 Pfizer shares in Q2 2026, an estimated $237K.
- Pfizer made up 0.06% of Summit Trail Advisors's portfolio in Q2 2026, its #181 holding.
- Summit Trail Advisors first reported a position in Pfizer in Q4 2017 and has held it in 28 quarters since.
- Summit Trail Advisors's Pfizer position peaked at $6.13M in Q1 2026.
- 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.